Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A-Reference-Cited by-同舟云学术

Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A

Published:2021-05-09 Issue:4 Volume:27 Page:626-633
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Astermark Jan¹²^ORCID,Olsson Anna³,Chelle Pierre⁴,Täckström Kinga⁵,Walger Maria⁵,Magnusson Maria⁶,Iorio Alfonso⁷⁸

Affiliation:

1. Department of Translational Medicine Lund University Malmö Sweden

2. Department of Hematology, Oncology and Radiation Physics Skåne University Hospital Malmö Sweden

3. Department of Medicine Region Västra Götaland Sahlgrenska University Hospital Gothenburg Sweden

4. School of Pharmacy University of Waterloo Waterloo Canada

5. Octapharma Nordic AB Stockholm Sweden

6. Karolinska Institutet Coagulation Unit Department of Hematology Department of Pediatrics, CLINTEC Clinical Chemistry & Coagulation, MMK Karolinska University Hospital Stockholm Sweden

7. Department of Health Research Methods, Evidence, and Impact McMaster University Hamilton ON Canada

8. Department of Medicine McMaster University Hamilton ON Canada

Funder

Octapharma

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14329

Reference17 articles.

1. Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment

2. Clotting factor concentrates given to prevent bleeding and bleeding‐related complications in people with haemophilia A or B;Iorio A;Cochrane Database Syst Rev,2011

3. Prophylaxis in haemophilia should be life‐long;Makris M;Blood Transfus,2012

4. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

5. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients;Haemophilia;2024-05-13

2. Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors;Haemophilia;2022-12-19